18 results
PRE 14A
NEXI
Neximmune Inc
13 Sep 23
Preliminary proxy
5:14pm
goals, market conditions, and the market perception of our business. You should also keep in mind that the implementation of the Reverse Stock Split
8-K
EX-99.1
NEXI
Neximmune Inc
5 Jun 23
NexImmune Presents Initial Positive Data in the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post
8:37am
. Jones.
Study Design
The goals of the NEXI-001 Phase 1 clinical trial are to evaluate the safety, tolerability, immune response, and clinical
DEF 14A
j53tipe94q6f
3 May 22
Definitive proxy
4:16pm
8-K
EX-99.1
6toxuf
17 Mar 22
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
4:15pm
10-K
mhnum3q1d9s 6epnc
31 Mar 21
Annual report
4:02pm
424B4
9d96yzr8 94mnwsj
16 Feb 21
Prospectus supplement with pricing info
4:38pm
S-1/A
EX-10.3.1
dkthje 2m
8 Feb 21
IPO registration (amended)
7:29am
S-1/A
nq3m f4k0
8 Feb 21
IPO registration (amended)
7:29am
S-1/A
EX-10.2.1
6o22y30kli kmet
8 Feb 21
IPO registration (amended)
7:29am
S-1/A
EX-10.4.1
hi4mzv d5fppiuoa
8 Feb 21
IPO registration (amended)
7:29am
S-1
31mpn
19 Jan 21
IPO registration
4:38pm
DRS/A
wvg3ao3y
15 Jan 21
Draft registration statement (amended)
12:00am
DRS
jg9il2f
14 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next